...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncogene >Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia|[sol]|lymphoma
【24h】

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia|[sol]|lymphoma

机译：达克珠单抗（抗-Tac，Zenapax）治疗白血病| [sol] |淋巴瘤

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with 90Y has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.
机译：达克珠单抗（Zenapax）识别白介素2（IL-2）受体的α亚基，并阻断该细胞因子与其生长因子受体的相互作用。选择IL-2受体α亚基作为单克隆抗体介导的白血病/淋巴瘤治疗靶标的科学依据是，正常细胞表达IL-2Rα的很少，而在患有多种白血病/淋巴瘤的患者中异常的T细胞淋巴恶性肿瘤表达该受体。 1997年，达克珠单抗被FDA批准用于预防肾移植排斥反应。此外，抗Tac为某些患有T细胞恶性肿瘤和多种炎症性自身免疫性疾病的患者提供了有效的治疗方法。最后，用这种具有90Y抗体的抗体进行的治疗已导致大多数成人T细胞白血病患者产生临床反应。这些有关IL-2 / IL-2受体系统的见解促进了针对某些白血病/淋巴瘤患者的有效达珠单抗抗体疗法的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号